Dietary sodium intake is a modifiable determinant of blood pressure, and impaired renal sodium handling contributes to the development of hypertension. It is unclear whether short-term changes in sodium intake alter the abundance of renal tubular sodium transporters in humans in vivo. The authors tested whether modulation of sodium intake in normotensive adults at elevated risk for hypertension changes the abundance of urinary extracellular vesicle (uEV) proteins that reflect nephron tubular transporter expression.
Forty-six normotensive adults with normal kidney function and at risk of developing hypertension were prospectively enrolled. Participants completed a controlled very low sodium (LS) diet followed by a high sodium (HS) diet. At the end of each dietary period, a 24-hour urine collection was obtained and used for quantification of uEV proteins. The investigators normalized uEV protein concentrations from those 24-hour collections for comparisons between diets.
Hormonal measurements included plasma and urinary aldosterone, renin activity, and urinary cortisol; the serum cortisol–cortisone ratio was also assessed. The study methods for statistical comparisons included Wilcoxon rank-sum tests to compare normalized uEV protein concentrations between diets and linear mixed effects models to test whether diet modified uEV protein associations with serum aldosterone, urinary aldosterone, and serum cortisol–cortisone ratio.
Dietary modulation produced marked differences in urinary sodium excretion. Participants achieved median [IQR] urine sodium of 13.2 [7.7–19.9] mEq/24h on the LS diet and 244.0 [197.1–297.0] mEq/24h on the HS diet, indicating effective separation of sodium intake conditions.
Hormonal responses to sodium modulation were consistent with physiological expectations: LS intake induced greater renin activity and greater plasma and urinary aldosterone, and lower urinary cortisol compared with HS intake.
Parallel to these hormonal changes, several key nephron transport-related proteins in uEVs showed diet-dependent abundance shifts. Normalized uEV concentrations of the thiazide-sensitive sodium-chloride cotransporter (NCC), the epithelial sodium channel (ENaC), the sodium–glucose cotransporter 2 (SGLT2), oxidative stress responsive kinase 1 (OXSR1), and Pendrin were significantly higher during LS intake than HS intake (p < 0.05 for all comparisons reported). Conversely, uEV concentrations of the calcium channel TRPV5 and the water channel AQP2 were lower during LS intake than HS intake (p < 0.001 for both).
These changes imply nephron-segment–specific responses to sodium intake: transporters and channels involved in sodium reabsorption and electrolyte handling exhibited differential abundance depending on sodium status.
Between-diet comparisons of normalized uEV protein concentrations were performed using Wilcoxon rank-sum tests. The investigators also employed linear mixed effects models to evaluate whether diet modified the relationships between uEV protein abundances and hormonal measures (serum aldosterone, urinary aldosterone, and serum cortisol–cortisone ratio). Specific parameter estimates, effect sizes, and full model outputs were not reported in the source summary.
Controlled dietary sodium modulation produced nephron-segment–specific changes in uEV protein abundance in this cohort of normotensive adults at risk for hypertension. The observed pattern—higher uEV NCC, ENaC, SGLT2, OXSR1, and Pendrin on low sodium and lower TRPV5 and AQP2 on low sodium—supports the concept that uEVs can be used as a noninvasive tool to probe in vivo renal sodium, water, and electrolyte handling.
These results provide proof-of-concept evidence that short-term dietary sodium changes are reflected in measurable alterations of tubular protein abundance in urinary vesicles. The source does not report downstream clinical outcomes or long-term follow-up in this summary.
Several authors reported consulting relationships unrelated to the present work: J.M.B. (AstraZeneca, Mineralys, Recordati Rare Diseases); A.V. (AstraZeneca, Corcept, Mineralys, Moderna, Vertex, Adaptyx, Esteve); J.M.L. (Mineralys). Other named authors reported no disclosures. The specific nature and financial details of the consulting relationships were not provided in the summary beyond the named companies.
The study was approved by the Mass General Brigham Institutional Review Board, and written informed consent was obtained from all participants. The authors state that all relevant ethical guidelines were followed and that trial registration or reporting obligations were met. The source indicates that all data produced in the study are available upon reasonable request to the authors; no public dataset link was reported in the summary.
The work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), grant R01DK115392. No additional funding details were reported in the provided source text.